Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Mar 11
Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026 Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026. Annuncio • Feb 26
Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026 Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026 Annuncio • Oct 24
Jacobio Pharma Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference Jacobio Pharma announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The pre-clinical results demonstrated that JAB-23E73 is a highly potent pan-KRAS (ON/OFF) inhibitor with strong selectivity that spares HRAS and NRAS inhibition. The compound exhibits superior antitumor activity across multiple cancer types harboring different KRAS driver mutations or amplification. In KRAS-driven mouse tumor models, JAB-23E73 induced tumor regression without causing significant body weight loss, indicating good tolerability and a wide therapeutic window. The compound also showed a favorable pharmacokinetic profile for oral administration and exhibited plasma drug concentration-dependent intratumoral p-ERK inhibition. Phase I clinical trials of JAB-23E73 are currently ongoing in both China and the United States for patients with advanced solid tumors harboring KRAS gene alterations. Annuncio • Aug 19
Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Annuncio • Jul 15
Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback for 78,873,528 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2025. Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences share repurchases on July 15, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 10, 2025. As per the mandate, the company is authorized to repurchase up to 78,873,528 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value per share and/or earnings per share for the company. The repurchases will be made out of the funds legally available for such purpose in accordance with the Articles of Association and the applicable laws of the Cayman Islands and the Listing Rules. The company may cancel such repurchased shares or hold them as treasury shares on or after the Rule Amendment Effective Date. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 10, 2025, the company has 791,755,080 shares in issue.
On July 14, 2025, the company announces a share repurchase program. Under the program, the company will repurchase up to HKD 100 million worth of its shares. The repurchase price of each share shall be no more than 5% higher than the average closing market price for the shares over the five trading days immediately preceding each repurchase. The company intends to fund the program from its own financial resources. Annuncio • Jul 03
Jacobio Pharma Submits Phase I/II Investigational New Drug Application for its Bet Inhibitor JAB-8263 for the Treatment of Autoimmune Diseases to the Center for Drug Evaluation in China Jacobio Pharma announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days. Previously, Jacobio has completed phase I clinical trials of JAB-8263 for solid tumor and hematological malignancies in both China and the United States. Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability. Annuncio • Jul 02
Jacobio Completes the First Patient Dage in the Phase I/IIa Clinical Trial of Pan-KRAS Inhibitor JAB-23E73 in U.S The board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS inhibitor JAB-23E73 in U.S. In parallel, the dose-escalation study in China is progressing as planned. KRAS mutations represent one of the most common oncogenic alterations in tumors, occurring in approximately 23%-25% of cancer patients. The mutation frequency is particularly high in pancreatic cancer (90%), colorectal cancer (40%), and non-small cell lung cancer (30%). An estimated 2.7 million newly diagnosed cancer patients worldwide are found to have tumor with KRAS mutations, underscoring the significant unmet need and the potential benefit of pan-KRAS inhibitors for this patient population. JAB-23E73 demonstrates high selectivity for KRAS, effectively inhibiting both the active ("On") and inactive ("Off") states of KRAS, with no inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73 has shown a favorable pharmacokinetic profile and promising anti-tumor activity in preclinical models. Annuncio • Mar 07
Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2024 Results on Mar 19, 2025 Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2024 results on Mar 19, 2025 Annuncio • Jan 07
Jacobio Pharma Announces the Registrational Clinical Data of Glecirasib Was Published in Nature Medicine Jacobio Pharma announced that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting. The pivotal phase II trial of glecirasib monotherapy demonstrated impressive efficacy, including the confirmed objective response rate of 47.9% (56/117), a median progression-free survival of 8.2 months, and a median overall survival of 13.6 months. Glecirasib has a manageable safety profile. Gleciasib has a favorable gastrointestinal safety profile compared with other KRAS G12C inhibitors. The new drug application of glecirasib is currently under evaluation by the Center for Drug Evaluation of the National Medical Products Administration of China, and has been granted Priority Review Designation. Annuncio • Dec 09
Jacobio Pharma Presents preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH Jacobio Pharmaceuticals Group Co., Ltd. presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California. The data showed that JAB-8263 was well tolerated with Recommended Phase 2 Dose (RP2D) being 0.3mg QD. The preliminary efficacy data for JAB-8263 monotherapy in MF are promising, as most patients demonstrated spleen volume reduction (SVR) and total symptom score (TSS) reduction. As of the data cutoff date of October 17, 2024, 16 patients with intermediate-/high-risk MF have been enrolled, and 13 patients have undergone at least one post-treatment efficacy assessment. All patients showed a mean SVR-19.95% at week 24 and -26.16% at best response. Two patients achieved =35% SVR, and an SVR of -34.9% was observed in one patient. Six of ten (60%) patients experienced a =50% reduction in TSS at week 24. The best response of SVR in 2 of 8 patients (JAK inhibitors-treated) was -41.2% and -34.9%, respectively. At week 24, 3 of 6 (50%) patients (JAK inhibitors-treated) achieved TSS50. Annuncio • Nov 27
Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dose in the Phase I/IIa Clinical Trial of Pan-Kras Inhibitor Jab-23E73 in China The board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS Inhibitor JAB-23E73 in China. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has shown a good pharmacokinetic profile. Annuncio • Oct 09
Jacobio Pharmaceuticals Group Co., Ltd. Presents the Pre-Clinical Data of Shp2 Inhibitorjab-3312 in Combination with Kras G12c Inhibitor Glecirasibat the Fifth Ras Initiative Symposium 2024 Jacobio Pharmaceuticals Group Co., Ltd. announced that the company presented the pre-clinical data of SHP2 inhibitor JAB-3312 in combo with KRAS G12C inhibitor Glecirasib as form of poster at the Fifth RAS Initiative Symposium 2024. The data showed that Glecirasib and JAB-3312 demonstrate potent anti-tumor effect both in vitro and in vivo, and JAB-3312 enhances the anti-tumor effect of Glecirasib. Representative patient cases were also included in the poster. The clinical data of the combination of JAB-3312 and Glecirasib also verified the above preclinical conclusions. The poster released by Jacobio at 2024 European Society for Medical Oncology (ESMO) Congress (ESMO 2024) showed that the confirmed objective response rate (cORR) of Glecirasib and JAB-3312 as first-line treatment for non-small cell lung cancer (NSCLC) was 70.6% (N=102), and the median progression-free survival (mPFS) remained stable at 12.2 months. Currently, a phase III registration clinical trial of JAB-3312 and Glecirasib for the treatment of first-line NSCLC harboring KRAS G12C mutation has been initiated in China. The Fifth RAS Initiative Symposium was held by Frederick National Laboratory which is affiliated with National Cancer Institute of the United States. Glecirasib (JAB-21822) is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with Glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor Glecirasib has been approved by the Center for Drug Evaluation of the National Medical Products Administration of China in February 2024. Reported Earnings • Oct 01
First half 2024 earnings released: CN¥0.22 loss per share (vs CN¥0.22 loss in 1H 2023) First half 2024 results: CN¥0.22 loss per share (further deteriorated from CN¥0.22 loss in 1H 2023). Net loss: CN¥169.1m (loss widened 1.7% from 1H 2023). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Annuncio • Sep 23
Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval from the U.S. FDA for Pan-KRAS Inhibitor JAB-23E73 JACOBIO PHARMACEUTICALS GROUP CO., LTD. announced that, the Food and Drug Administration of the United States has approved the Investigational New Drug application of its self-developed drug JAB-23E73 (Pan-KRAS Inhibitor), and plans to initiate phase I/IIa clinical trial in advanced solid tumor patients. The IND in China has been submitted to the Center for Drug Evaluation of the National Medical Product Administration of the PRC, and the clinical trial in China will be conducted after China IND approval. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has showed a good pharmacokinetic profile. Annuncio • Aug 30
Jacobio Pharmaceuticals Group Co., Ltd. Announces Board Changes Jacobio Pharmaceuticals Group Co., Ltd. announced that Ms. Yanmin TANG (" Ms. Tang ") has tendered her resignation from the position as a non-executive Director with effect from August 30, 2024 due to her pursuit of other personal affairs. Accordingly, Ms. Tang will cease to be a member of the nomination committee of the Company (the "Nomination Committee") and the remuneration committee of the Company (the "Remuneration Committee") with effect from August 30, 2024. Ms. Tang confirmed that she The Board further announces that, Dr. Te-li CHEN, a non-executive Director, has been appointed as a member of the Nomination Committee and the Remuneration Committee in place of Ms. Tang with effect from August 30, 2024, respectively. Annuncio • Aug 20
Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Annuncio • Aug 07
Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dosing in the Phase III Clinical Trial of Glecirasib in Combination with Glecirasib The board of directors of Jacobio Pharmaceuticals Group Co., Ltd. announced that the Company has completed the first patient dosage in the Phase III clinical trial of KRAS G12C inhibitor Glecirasib in combination with the SHP2 inhibitor JAB-3312 versus standard care (chemotherapy plus anti-PD-1 antibody) in front-line KRAS G12C mutant non-small cell lung cancer (NSCLC). JAB-3312 is the first SHP2 inhibitor that entered a registration clinical trial globally. The new drug application (NDA) of Glecirasib monotherapy for the second-line and beyond NSCLC with KRAS G12C mutation was granted Priority Review designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on May 21, 2024. According to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024, Glecirasib in combined with JAB-3312 resulted confirmed objective response rate (cORR) of 64.7% (66/102) and preliminary median progression-free survival (mPFS) of 12.2 months in the front-line NSCLC. The optimal dosing schedule Glecirasib at 800mg daily combined with JAB-33 12 at 2mg daily one week on and one week off resulted a cORR of 77.4% (24/31), and 54.8% (17/31) of patients achieved a deep response with tumors shrinking by more than 50%. Regarding on the safety data from all study patients the incidence of grade 3 or 4 treatment-related adverse events (TRAE) was 43.8%, and there was no treatment-related death. The overall safety is manageable. Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. A number of Phase I/II clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include a pivotal clinical trial in NSCLC in China, combination therapy trials with SHP2 inhibitor JAB -3312 in NSCLC and with cetuximab in colorectal cancer, and a registrational pivotal clinical trial of single agent for pancreatic cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with the best-in-class potential. Jacobio is currently conducting multiple clinical trials of JAB-3312 in China, the United States, the United States and Europe, including the combination therapy trial with Glecirasib. The Phase III study in combination with KRAS G12C inhibitorlecirasib has been approved in China in February 2024. Board Change • Jun 26
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.